Literature DB >> 21348950

Random treatment assignment using mathematical equipoise for comparative effectiveness trials.

Harry P Selker1, Robin Ruthazer, Norma Terrin, John L Griffith, Thomas Concannon, David M Kent.   

Abstract

In controlled clinical trials, random assignment of treatment is appropriate only when there is equipoise, that is, no clear preference among treatment options. However, even when equipoise appears absent because prior trials show, on average, one treatment yields superior outcomes, random assignment still may be appropriate for some patients and circumstances. In such cases, enrollment into trials may be assisted by real-time patient-specific predictions of treatment outcomes, to determine whether there is equipoise to justify randomization. The percutaneous coronary intervention thrombolytic predictive instrument (PCI-TPI) computes probabilities of 30-day mortality for patients having ST elevation myocardial infarction (STEMI), if treated with thrombolytic therapy (TT), and if treated with PCI. We estimated uncertainty around differences in their respective predicted benefits using the estimated uncertainty of the model coefficients. Using the 2,781-patient PCI-TPI development dataset, we evaluated the distribution of predicted benefits for each patient. For three typical clinical situations, randomization was potentially warranted for 70%, 93%, and 80% of patients. Predictive models may allow real-time patient-specific determination of whether there is equipoise that justifies trial enrollment for a given patient. This approach may have utility for comparative effectiveness trials and for application of trial results to clinical practice.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21348950      PMCID: PMC3076795          DOI: 10.1111/j.1752-8062.2010.00253.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  22 in total

1.  Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group.

Authors:  P M Rothwell; C P Warlow
Journal:  Lancet       Date:  1999-06-19       Impact factor: 79.321

2.  Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?

Authors:  Adrián V Hernández; Eric Boersma; Gordon D Murray; J Dik F Habbema; Ewout W Steyerberg
Journal:  Am Heart J       Date:  2006-02       Impact factor: 4.749

3.  Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument.

Authors:  H P Selker; J L Griffith; J R Beshansky; C H Schmid; R M Califf; R B D'Agostino; M M Laks; K L Lee; C Maynard; R H Selvester; G S Wagner; W D Weaver
Journal:  Ann Intern Med       Date:  1997-10-01       Impact factor: 25.391

4.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.

Authors:  Richard L Kravitz; Naihua Duan; Joel Braslow
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

5.  Equipoise and the ethics of clinical research.

Authors:  B Freedman
Journal:  N Engl J Med       Date:  1987-07-16       Impact factor: 91.245

6.  Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy.

Authors:  Peter M Rothwell; Ziyah Mehta; Sally C Howard; Sergei A Gutnikov; Charles P Warlow
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

7.  Can overall results of clinical trials be applied to all patients?

Authors:  P M Rothwell
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

8.  Ethical and scientific features of cutoff-based designs of clinical trials: a simulation study.

Authors:  J C Cappelleri; W M Trochim
Journal:  Med Decis Making       Date:  1995 Oct-Dec       Impact factor: 2.583

9.  Clinical and prophylactic trials with assured new treatment for those at greater risk: I. A design proposal.

Authors:  M O Finkelstein; B Levin; H Robbins
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

10.  Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis.

Authors:  Rodney A Hayward; David M Kent; Sandeep Vijan; Timothy P Hofer
Journal:  BMC Med Res Methodol       Date:  2006-04-13       Impact factor: 4.615

View more
  6 in total

1.  EFFICACY-TO-EFFECTIVENESS CLINICAL TRIALS.

Authors:  Harry P Selker; Sheeona Gorman; Kenneth I Kaitin
Journal:  Trans Am Clin Climatol Assoc       Date:  2018

2.  Open clinical trial data for all? A view from regulators.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Hubert Leufkens; Guido Rasi
Journal:  PLoS Med       Date:  2012-04-10       Impact factor: 11.069

3.  Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice.

Authors:  Harry P Selker; Hans-Georg Eichler; Norman L Stockbridge; Newell E McElwee; Willard H Dere; Theodora Cohen; John K Erban; Vicki L Seyfert-Margolis; Peter K Honig; Kenneth I Kaitin; Kenneth A Oye; Ralph B D'Agostino
Journal:  Clin Pharmacol Ther       Date:  2019-02-12       Impact factor: 6.875

4.  The use of patient-specific equipoise to support shared decision-making for clinical care and enrollment into clinical trials.

Authors:  Harry P Selker; Denise H Daudelin; Robin Ruthazer; Manlik Kwong; Rebecca C Lorenzana; Daniel J Hannon; John B Wong; David M Kent; Norma Terrin; Alejandro D Moreno-Koehler; Timothy E McAlindon
Journal:  J Clin Transl Sci       Date:  2019-02

5.  An example of medical device-based projection of clinical trial enrollment: Use of electrocardiographic data to identify candidates for a trial in acute coronary syndromes.

Authors:  Harry P Selker; Manlik Kwong; Robin Ruthazer; Sheeona Gorman; Giuliana Green; Elizabeth Patchen; James E Udelson; Howard A Smithline; Michael R Baumann; Paul A Harris; Rashmee U Shah; Sarah J Nelson; Theodora Cohen; Elizabeth B Jones; Brien A Barnewolt; Andrew E Williams
Journal:  J Clin Transl Sci       Date:  2018-12

6.  A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials.

Authors:  H P Selker; K A Oye; H-G Eichler; N L Stockbridge; C R Mehta; K I Kaitin; N E McElwee; P K Honig; J K Erban; R B D'Agostino
Journal:  Clin Pharmacol Ther       Date:  2013-09-23       Impact factor: 6.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.